Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.

Saved in:
Bibliographic Details
Title: Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.
Authors: Kissling E; Epiconcept, Paris, France., Hooiveld M; Nivel, Utrecht, the Netherlands., Sandonis Martín V; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain., Martínez-Baz I; Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain., William N; Public Health Scotland, Glasgow, Scotland., Vilcu AM; INSERM, Sorbonne Université, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France., Mazagatos C; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain., Domegan L; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland., de Lusignan S; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.; Royal College of General Practitioners Research and Surveillance Centre, London, UK., Meijer A; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands., Machado A; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal., Brytting M; The Public Health Agency of Sweden, Stockholm, Sweden., Casado I; Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain., Murray JK; Public Health Scotland, Glasgow, Scotland., Belhillil S; Unité de Génétique Moléculaire des Virus à ARN, UMR 3569 CNRS, Université Paris Diderot SPC, Institut Pasteur, Paris, France.; CNR des virus des infections respiratoires, Institut Pasteur, Paris, France., Larrauri A; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain., O'Donnell J; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland., Tsang R; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.; Royal College of General Practitioners Research and Surveillance Centre, London, UK., de Lange M; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands., Rodrigues AP; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal., Riess M; The Public Health Agency of Sweden, Stockholm, Sweden., Castilla J; Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain., Hamilton M; Public Health Scotland, Glasgow, Scotland., Falchi A; Laboratoire de Virologie, Université de Corse-Inserm, Corte, France., Pozo F; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain., Dunford L; National Virus Reference Laboratory, University College Dublin, Dublin, Ireland., Cogdale J; Public Health England, London, England., Jansen T; Nivel, Utrecht, the Netherlands., Guiomar R; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal., Enkirch T; The Public Health Agency of Sweden, Stockholm, Sweden., Burgui C; Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain., Sigerson D; Public Health Scotland, Glasgow, Scotland., Blanchon T; INSERM, Sorbonne Université, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France., Martínez Ochoa EM; Servicio de Epidemiología y Prevención Sanitaria, Dirección General de Salud Pública, Consumo y Cuidados, La Rioja, Spain., Connell J; National Virus Reference Laboratory, University College Dublin, Dublin, Ireland., Ellis J; Public Health England, London, England., van Gageldonk-Lafeber R; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands., Kislaya I; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal., Rose AM; Epiconcept, Paris, France., Valenciano M; Epiconcept, Paris, France.
Corporate Authors: I-MOVE-COVID-19 primary care study team; The members of the I-MOVE-COVID-19 primary care study team are listed in the Investigators tab., I-MOVE-COVID-19 primary care study team (in addition to authors above)
Source: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2021 Jul; Vol. 26 (29).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1560-7917
DOI:10.2807/1560-7917.ES.2021.26.29.2100670